Next Phase Newsletter

The firm is a NASDAQ-listed company that acquires, develops and commercializes promising drugs and technologies by forming and financing subsidiary companies.

All member companies have access to resources necessary for cultivating and maintaining their business such as scientific, clinical, regulatory, manufacturing, legal and financial expertise. Among these key resources are committed investment capital, experienced start-up management with in-house Entrepreneurs in Residence (EIRs), world-class scientific expertise, and shared facilities.

The company does not make equity only investments, but is open to a variety of deal structures to license, co-develop or acquire assets, including traditional milestone-based licensing deals, joint ventures, and option agreements with equity arrangements.

The company focuses primarily on therapeutic opportunities, but will also consider drug delivery devices/technologies. Our current areas of interest include:

– Late clinical stage or marketed dermatology programs/products

– IND ready, clinical or marketed rare disease, oncology, neurology, opthamology, GI or Hepatology

The company has no management team requirements and will work with entrepreneurs of all experience levels coming from academia or industry, and has no restriction on the geographic location of companies or technologies.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The venture fund is a healthcare-focused venture capital firm formed in 2017 through the merger of two previous funds. The firm has offices in Shanghai, Hong Kong, Boston, and San Francisco. The firm currently manages 2 funds: a $533M USD fund and a RMB 2.06B fund. The firm generally seeks to make equity investments into emerging life science companies in seed and venture stages; however, the fund also considers commercial-stage companies, depending on the opportunity. The investment size of the USD fund ranges from $5 – $25 million. For the RMB fund, typical investment size is RMB 30- RMB150 million. The firm currently focuses on China-based companies or overseas businesses with a China angle.

The firm is looking for new investment opportunities across a wide spectrum of life science sectors, including Therapeutics, Diagnostics, Biotech R&D Services, Medical Technology and Healthcare IT. The firm is agnostic to disease indications but is most interested in areas with large market potential, including Diabetes, Cardiovascular, Musculoskeletal System and Connective Tissue, Diseases of the Eye and Oncology. Rare diseases are generally less of interest. The firm is open to invest in both small molecules and biologics, and it looks for all classes of devices. The funds are most interested in companies in preclinical and early-clinical stage, but they are open to companies in late-clinical and growth stage, on a case-by-case basis.

The firm will only invest in private companies. The firm is looking to be an active investor, sometimes taking a board seat post-investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The company is a publicly traded pharmaceutical company founded in 1926 and based in Europe. The firm has over €1.3 billion in annual revenues.

The company is interested in licensing and M&A opportunities in its core therapeutic areas of urology, cardiovascular, gastrointestinal and metabolic diseases, and also in all rare disease/orphan drug assets. The company will consider partnerships worldwide. Particularly in the rare disease space, The firm prefers to invest in global rights.

The company is interested in early stage therapeutic partnerships in rare diseases, including in preclinical assets provided that there is strong preclinical proof of concept data for the asset (such as strong efficacy data from an animal model that are relevant and reflective of the human condition). The firm generally does not invest in rare oncology assets but is otherwise open to a wide range of rare disease opportunities. In other core areas (urology, cardiovascular, gastrointestinal, and central nervous system) the firm prefers to partner with companies that have obtained solid human proof of concept data. The firm can be a hands-on development and manufacturing partner in small molecule therapeutics, but not in biologics or cell therapies.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

A private/family investment vehicle based in CA is making seed investments via an accelerator arm, and also has a stage-agnostic fund. Seed investments are typically $25,000-100,000, and the firm is capable of making larger investments via the fund. The firm also provides a three-month accelerator program, and works with partners in the healthcare industry to strategically invest in startups. The firm will consider investing in companies worldwide.

The firm is interested in investing in digital health and medical technology, and invests in subsectors in which the firm and its industry partners can apply expertise; within medical devices, typically this means products that have a significant software component, including biosensors, wearables and health monitoring devices. Within digital health, the firm’s interests include the following areas: Care Management, Hospital Workflow, Diagnostics, A.I. & Big Data, Population Health, Patient Adherence, Telemedicine. The firm is interested in both consumer applications and enterprise software. The firm works with strategic partners (including major pharma companies and health systems) to identify focus areas for innovation.

The firm prefers to invest in companies with at least two co-founders, one with technical expertise and one with business expertise; for the accelerator program in particular, the firm prefers to work with companies that have a technical expert co-founder. In addition to due diligence on the management team and technology, the firm also considers a product’s potential market

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

A biotech early stage investment firm was founded in 2016 and headquartered in Taipei, Taiwan. The firm invests from an Evergreen Fund backed by a Family Office. The firm has a fund size of $50M and an average ticket size range from $250K to $1M. The firm mainly focuses on early-stage biotechnology and medical device companies and is looking to invest in seed to pre-A round.

The firm is looking for new investment opportunities across a wide spectrum of life science sectors. The current pipeline includes biotechnology platforms, medical devices, therapeutics and service platforms.

The firm does not have any specific requirements for companies and their management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The firm is a healthcare-focused venture investment fund. The core members are all trained in biomedical fields, with healthcare industry experience and years of successful investment or entrepreneurship experience in China. The firm past investment portfolio companies cover areas such as drug, device, diagnostics, healthcare IT and medical services. These investments were over $10MM and were made in venture rounds from Series A-C. The firm currently manages both RMB and US Dollar funds, investing in early and growth-stage companies in China and overseas. The firm believes in the huge industry growth and significant investment opportunities in China healthcare space for the next 10 to 20 years.

The firm has invested in therapeutics in a wide range of indications, including cancer, infectious diseases and autoimmune disorders. These investments covered a wide range of modalities including small molecules, antibodies and gene therapies. The firm additionally invested in medical device and imaging technologies, such as ultrasound and cardiovascular devices. Therapeutic investments were made during pre-clinical trials, while device investments were made pre-market. The firm invested in bioinformatics, research tools and animal medicine as well. The firm has invested in companies in the US, China and Western Europe.

The firm has no specific management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.